The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Shah Sujal since 2014.
This trader's CIK number is 1588861.
At the time of last reporting, Shah Sujal was the Chief Executive Officer of Cymabay Therapeutics, Inc.. (stock ticker symbol CBAY).
Also see all insider trading activities at Cymabay Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | CBAY | 0 | $0 | 129,726 | $2,244,401 | 129,726 | $648,630 |
| 2022 | CBAY | 51,301 | $100,036 | 0 | $0 | 0 | $0 |
| 2019 | CBAY | 10,000 | $49,155 | 0 | $0 | 0 | $0 |
| 2018 | CBAY | 25,000 | $222,650 | 0 | $0 | 0 | $0 |
| 2017 | CBAY | 10,000 | $73,140 | 0 | $0 | 0 | $0 |
| 2016 | CBAY | 55,000 | $76,449 | 0 | $0 | 0 | $0 |
| 2015 | CBAY | 10,000 | $34,000 | 0 | $0 | 0 | $0 |
| 2014 | CBAY | 10,000 | $74,400 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-12-11 | CBAY | Option Ex | 64,865 | 5.00 | 324,325 |
| 2023-12-11 | CBAY | Sale | 64,865 | 20.40 | 1,323,116 |
| 2023-10-09 | CBAY | Sale | 64,861 | 14.20 | 921,285 |
| 2023-10-09 | CBAY | Option Ex | 64,861 | 5.00 | 324,305 |
| 2022-06-06 | CBAY | Buy | 51,301 | 1.95 | 100,036 |
| 2019-10-10 | CBAY | Buy | 5,000 | 4.30 | 21,500 |
| 2019-09-20 | CBAY | Buy | 1,900 | 5.50 | 10,450 |
| 2019-09-23 | CBAY | Buy | 3,100 | 5.55 | 17,205 |
| 2018-12-21 | CBAY | Buy | 10,000 | 6.54 | 65,400 |
| 2018-10-15 | CBAY | Buy | 5,000 | 9.90 | 49,500 |
| 2018-07-27 | CBAY | Buy | 5,000 | 10.90 | 54,500 |
| 2018-05-11 | CBAY | Buy | 5,000 | 10.65 | 53,250 |
| 2017-07-20 | CBAY | Buy | 10,000 | 7.31 | 73,140 |
| 2016-04-04 | CBAY | Buy | 22,000 | 1.39 | 30,579 |
| 2016-04-05 | CBAY | Buy | 33,000 | 1.39 | 45,870 |
| 2015-05-18 | CBAY | Buy | 10,000 | 3.40 | 34,000 |
| 2014-09-16 | NONE | Buy | 10,000 | 7.44 | 74,400 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Shah Sujal (Chief Executive Officer of Cymabay Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.